Figure 2 — Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis

Navigate

Research Paper|Volume 13, Issue 11|pp. 15413–15432

100%

Figure 2.Overall survival hazard ratio in female patients in the immune checkpoint inhibitor group compared with the control group.

Figure 2 — Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis | Aging